Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conclusion of HIT Study

8 Apr 2011 07:00

RNS Number : 5457E
Akers Biosciences, Inc.
08 April 2011
 

Embargoed: 0700hrs 8 April 2011

Akers Biosciences, Inc.

("ABI" or the "Company")

 

Conclusion of First Heparin-induced Thrombocytopenia Study

 

Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the results of a study recently concluded at the University of Miami/Jackson Memorial Hospital, which included an analysis of ABI's PIFA Heparin/PF-4 Rapid Assay ("PIFA test"), as well as several different laboratory methods in the screening for heparin-induced thrombocytopenia ("HIT") in critically ill patients.

 

The Company is pleased to announce that not only did its PIFA test correctly identify every positive patient but, more importantly, it produced no "false negative" results, unlike the alternative ELISA test. The study concluded that ABI's unique, patented PIFA assay can serve as a quick "rule out" test for HIT, thus assisting the physician in the rapid diagnosis of the patient's potentially serious condition.

 

In the US and EU, approximately 25 million patients are exposed to Heparin annually and 1 to 5% of those patients receive a HIT diagnosis. The largest at-risk populations are patients undergoing major cardiac or orthopedic surgical procedures. It is estimated that up to 50% of cardiac surgery patients develop HIT-antibodies, while these antibodies may be detected in close to 15% of orthopedic surgery patients. Patients with HIT are at risk of developing limb- and life-threatening complications, so the timely test result provided by ABI's PIFA test, is paramount to effective, clinical decision making.

 

Daniel Kett, M.D, one of the principal investigators of the ABI-funded study, was invited to present the conclusions at the 31st International Symposium of Intensive Care and Emergency Medicine last week in Brussels. Significantly, Dr. Kett and his colleagues proposed a new algorithm in the diagnosis of HIT that uses ABI's PIFA test, which could have an impact on how HIT patients are detected and managed.

 

The Company's new point-of care testing platform for HIT antibodies, PIFA POC, was also introduced as, with the benefit of its patented integrated blood cell separator, it will further reduce the time to diagnosis to approximately 2 minutes.

 

Dr. Kett's presentation was entitled "Heparin induced thrombocytopenia in the critically ill: How to interpret anti-PF4 antibody test results".

 

Dr. Raymond Akers, Founder & Executive Chairman of ABI, commented,

 

"We are pleased to see our test used so successfully in a clinical situation, and also that the authors thought highly enough of our product to include it in their new diagnostic algorithm for HIT. When a physician encounters a life and death situation like HIT, he or she needs a product that can be entirely relied upon to provide critical information in a timely manner. This study is a validation of our product's performance. We believe that the positive experiences reported in this study are similar to those in other institutions, and have contributed to the increase in the market penetration of this product that we have observed this year."

 

Enquiries:

 

Thomas A. Nicolette, President and CEO

Dr Raymond F. Akers, Jr., Executive Chairman

Tel. +1 856 848 8698

Antony Legge or Noelle Greenaway

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIRMLTMBJMBMB
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.